Back to news

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

PR Newswire•19/11/2026•02:07 ET
0

Key Highlights

  • ➤Second FDA IND acceptance advances Evotec-Bristol Myers Squibb molecular glue pipeline
  • ➤Second CELMoD candidate expected to enter Phase 1 clinical trial in 2027
  • ➤First partnership candidate entered Phase 1 trial in March 2026
  • ➤2018 partnership expanded in 2022 to develop molecular glue degraders

Expert Statements

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec

“The progression of a second molecular glue candidate to IND acceptance demonstrates the repeatability and productivity of our discovery platform. We are systematically translating complex biology into development candidates. This achievement reinforces the value of our longstanding collaboration with Bristol Myers Squibb and further strengthens our confidence in the platform's potential to generate a growing pipeline of investigational drug candidates aimed at addressing substantial unmet medical needs.”

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance PR Newswire

* FDA clearance expands partnered molecular glue pipeline * Achievement underscores productivity of the collaboration in molecular glue discovery and potential to address patient populations with high unmet need HAMBURG, Germany, Nov. 19, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that its strategic protein degradation partnership with Bristol Myers Squibb has received a second Investigational New Drug (IND) acceptance from the U.S. Food and Drug Administration (FDA). The first candidate produced under the partnership entered a Phase 1 clinical trial in advanced clear cell renal cell carcinoma in March 2026 . The second accepted investigational drug candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter a Phase 1 clinical trial in 2027.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in